An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes

[1]  E. Albert,et al.  Characterization of DR blank alleles by restriction fragment length polymorphism (RFLP). , 2008, Tissue antigens.

[2]  E. Albert,et al.  Brief summary of Ninth International Histocompatibility Workshop. , 2008, Tissue antigens.

[3]  L. Hammarström,et al.  HL-A8 and LD-8a in patients with myasthenia gravis. , 2008, Tissue antigens.

[4]  M. Weissel.  Graves’ Disease and Myasthenia Gravis , 2002 .

[5]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[6]  F. Bach,et al.  HLA and disease--the perils of simplification. , 1990, The New England journal of medicine.

[7]  F. Christiansen,et al.  Differences in gene copy number carried by different MHC ancestral haplotypes. Quantitation after physical separation of haplotypes by pulsed field gel electrophoresis , 1990, The Journal of experimental medicine.

[8]  J. Strominger,et al.  Human major histocompatibility complex contains a minimum of 19 genes between the complement cluster and HLA-B. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[9]  F. Christiansen,et al.  Some disease-associated ancestral haplotypes carry a polymorphism of TNF. , 1989, Human immunology.

[10]  T. Strachan,et al.  Pulsed field gel electrophoresis identifies a high degree of variability in the number of tandem 21‐hydroxylase and complement C4 gene repeats in 21‐hydroxylase deficiency haplotypes. , 1989, The EMBO journal.

[11]  V. Wong,et al.  Possible evidence for a variant of myasthenia gravis based on HLA and acetylcholine receptor antibody in Chinese patients. , 1989, The Quarterly journal of medicine.

[12]  F. Christiansen,et al.  Extensive deletions and insertions in different MHC supratypes detected by pusled field gel electrophoresis , 1988, The Journal of experimental medicine.

[13]  P. White,et al.  Molecular genetic analysis of nonclassic steroid 21-hydroxylase deficiency associated with HLA-B14,DR1. , 1988, The New England journal of medicine.

[14]  P. White,et al.  Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Ghezzi,et al.  Enhancement of in vivo immune response by tumor necrosis factor. , 1987, Journal of immunology.

[16]  H. Colten,et al.  Polymorphism of the human complement C4 and steroid 21-hydroxylase genes. Restriction fragment length polymorphisms revealing structural deletions, homoduplications, and size variants. , 1986, The Journal of clinical investigation.

[17]  P. White,et al.  Structure of human steroid 21-hydroxylase genes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Rassenti,et al.  HLA-DQ BETA-CHAIN POLYMORPHISM LINKED TO MYASTHENIA GRAVIS , 1986, The Lancet.

[19]  K. Lam,et al.  HLA antigens and acetylcholine receptor antibody in the subclassification of myasthenia gravis in Hong Kong Chinese. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[20]  A. Wilton,et al.  Rearrangement of 21-hydroxylase genes in disease-associated MHC supratypes , 1986, Immunogenetics.

[21]  F. Christiansen,et al.  Myasthenia gravis and HLA antigens in American blacks and other races , 1985, Journal of Neuroimmunology.

[22]  K. C. Reed,et al.  Rapid transfer of DNA from agarose gels to nylon membranes. , 1985, Nucleic acids research.

[23]  K. Belt,et al.  Deletion of complement C4 and steroid 21‐hydroxylase genes in the HLA class III region. , 1985, The EMBO journal.

[24]  Bharat B. Aggarwal,et al.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin , 1984, Nature.

[25]  M. Satake,et al.  HLA antigens in Japanese patients with narcolepsy , 1984 .

[26]  K. Belt,et al.  The structural basis of the multiple forms of human complement component C4 , 1984, Cell.

[27]  F. Christiansen,et al.  Complement allotyping in SLE: association with C4A null. , 1983, Australian and New Zealand journal of medicine.

[28]  K. Walton,et al.  Penicillamine-induced myasthenia in rheumatoid arthritis: its clinical and genetic features. , 1983, Annals of the rheumatic diseases.

[29]  A. Feinberg,et al.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. , 1983, Analytical biochemistry.

[30]  J. McCluskey,et al.  Disease Associations with Complotypes, Supratypes and Haplotypes , 1983, Immunological reviews.

[31]  A. Svejgaard,et al.  HLA and Disease 1982 ‐ A Survey , 1983, Immunological reviews.

[32]  P. Kay,et al.  The diagnostic significance of autoantibodies to the acetylcholine receptor. , 1982, Journal of neuroimmunology.

[33]  F. Christiansen,et al.  Prevalence of ankylosing spondylitis and radiological abnormalities of the sacroiliac joints in HLA-B27 positive individuals. , 1981, The Journal of rheumatology.

[34]  M. New,et al.  Congenital adrenal hyperplasia. , 1981, Clinical biochemistry.

[35]  L. Hammarström,et al.  HLA-A, -B, -C and -D antigens in male patients with myasthenia gravis. , 1978, Tissue antigens.

[36]  F. Ersoy,et al.  HLA antigens associated with Behçet's disease. , 1977, Archives of dermatology.

[37]  J. Lindstrom,et al.  Antibody to acetylcholine receptor in myasthenia gravis , 1976, Neurology.

[38]  J. Lindstrom,et al.  Antibody to acetylcholine receptor in myasthenia gravis , 1976, Neurology.

[39]  D. Elmqvist.  Myasthenia Gravis , 1975, The Lancet.

[40]  J. Patrick,et al.  Autoimmune Response to Acetylcholine Receptor , 1973, Science.

[41]  P I Terasaki,et al.  High association of an HL-A antigen, W27, with ankylosing spondylitis. , 1973, The New England journal of medicine.

[42]  C. Alper,et al.  GENETIC POLYMORPHISM IN HUMAN GLYCINE-RICH BETA-GLYCOPROTEIN , 1972, The Journal of experimental medicine.

[43]  P. Smith,et al.  Congenital Adrenal Hyperplasia , 1970 .

[44]  R. Pirskanen,et al.  Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis , 2005, Immunogenetics.

[45]  A. Whitehead,et al.  Haplotypic polymorphisms of the TNFB gene , 2004, Immunogenetics.

[46]  P. Kay,et al.  Susceptibility to IDDM Is marked by MHC supratypes rather than individual alleles , 2004, Immunogenetics.

[47]  E. Yunis,et al.  Molecular analysis distinguishes two HLA-DR3-bearing major histocompatibility complex extended haplotypes , 2004, Immunogenetics.

[48]  J. Kramer,et al.  Usefulness of densitometry in typing of human complement component C4 , 2004, Immunogenetics.

[49]  R. Campbell,et al.  HLA Class III Region , 1998 .

[50]  F. Christiansen,et al.  Conservation Versus Polymorphism of the MHC in Relation to Transplantation, Immune Responses and Autoimmune Disease , 1991 .

[51]  M. French,et al.  Central MHC genes, IgA deficiency and autoimmune disease. , 1990, Immunology today.

[52]  F. Christiansen,et al.  The Genomic Structure of Ancestral Haplotypes Revealed by Pulsed Field Gel Electrophoresis (PFGE) , 1989 .

[53]  E. Albert,et al.  Myasthenia Gravis: Joint Report , 1989 .

[54]  P. Kay,et al.  C4 allotyping on plasma or serum: application to routine laboratories. , 1988, Human immunology.

[55]  R. Dawkins,et al.  D-Penicillamine-Induced Myasthenia Gravis , 1984 .

[56]  M. Baur,et al.  Insulin-Dependent Diabetes Mellitus , 1984 .

[57]  E. Yunis,et al.  Extended HLA/complement allele haplotypes: evidence for T/t-like complex in man. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Svejgaard.  HLA and disease. , 1977, Revue francaise de transfusion et immuno-hematologie.

[59]  C. Alper,et al.  GENETIC P OLYMORPHISM IN HUMAN G LYCINE-RICH BETA-GLYCOPROTEI N*, { , 1972 .